Teladoc CFO vesting: 8,333 RSUs convert, 2,972 shares sold

Rhea-AI Filing Summary

Joseph Ronald Catapano, Chief Accounting Officer of Teladoc Health, Inc. (TDOC), reported the vesting and partial sale of restricted stock units. On 10/01/2025 8,333 restricted stock units converted to 8,333 shares of common stock. On 10/02/2025 he sold 2,972 shares at $7.885 per share to cover tax withholding, leaving 5,361 shares beneficially owned following the sale. The filing notes the RSU grant of 25,000 units on 10/01/2024 with one-third vesting on the first anniversary and the remainder vesting in eight substantially equal quarterly installments.

Positive

• 8,333 restricted stock units converted to 8,333 shares on 10/01/2025, reflecting scheduled compensation vesting
• Sell-to-cover transaction retained a majority of the vested shares: 5,361 shares remain beneficially owned after the sale

Negative

• A partial disposition of vested shares: 2,972 shares sold at $7.885 on 10/02/2025

Insights

Compensation & Accounting Expert

RSU vesting and sell-to-cover taxes recorded; compensation realized but mostly retained.

The filing records conversion of 8,333 restricted stock units into 8,333 shares on 10/01/2025, consistent with the disclosed 25,000 RSU grant from 10/01/2024. This reflects scheduled employee compensation vesting rather than a discretionary open-market sale.

The sale of 2,972 shares at $7.885 on 10/02/2025 is explicitly described as a sale to cover tax withholding, leaving 5,361 shares retained. For accounting purposes, such sell-to-cover transactions recognize compensation expense at vesting and reduce share-based holdings; the filing provides the necessary quantities and price.

Insider Transaction Analyst

Insider sold a portion of vested shares at a reported price; remaining holdings disclosed.

The report shows a disposition of 2,972 shares at $7.885, reducing beneficial ownership to 5,361 shares after the transaction. All transactions are labeled as direct ownership and are reported under Section 16 rules.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Catapano Joseph Ronald

(Last) (First) (Middle)

C/O TELADOC HEALTH, INC.,

155 E 44TH ST, FLOOR 17

(Street)

NEW YORK NY 10017

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Teladoc Health, Inc. [ TDOC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/01/2025		M		8,333	A	(1)	8,333	D
Common Stock	10/02/2025		S(2)		2,972	D	$7.885	5,361	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	10/01/2025		M			8,333	(3)	(3)	Common Stock	8,333	$0	16,667	D

Explanation of Responses:

1. Restricted stock units convert to shares of TDOC common stock on a one-for-one basis.

2. Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's restricted stock unit awards.

3. On October 1, 2024, the reporting person was granted 25,000 restricted stock units, vesting one-third on the first anniversary of the grant date, with the remainder vesting in eight substantially equal quarterly installments thereafter.

Remarks:

	/s/ Adam C. Vandervoort, Attorney-in-Fact	10/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did TDOC's Chief Accounting Officer report?

The filing shows conversion of 8,333 RSUs to 8,333 shares on 10/01/2025 and a sale of 2,972 shares at $7.885 on 10/02/2025 to cover taxes.

How many RSUs was Joseph Catapano granted and what is the vesting schedule?

The filing discloses a grant of 25,000 RSUs on 10/01/2024, with one-third vesting on the first anniversary and the remainder vesting in eight substantially equal quarterly installments.

How many TDOC shares does Catapano beneficially own after the transactions?

Following the reported transactions, the filing shows Catapano beneficially owns 5,361 shares.

What was the purpose of the share sale reported on 10/02/2025?

The filing states the 2,972 shares were sold to cover the tax withholding obligation related to RSU vesting.

Was the Form 4 filed jointly or by one reporting person?

The form was filed by one reporting person.